Buy, sell, hold:
11 stocks that analysts are watching out today Nomura has a buy ratings on Dr Reddy’s, Glenmark, Alkem, Cadila and Jubilant Life. It says Teva’s 2017 guidanceis lower than what was presented in 2016-2020 prelim outlook and implies a shortfall of USD 1.5-2 billion in EBITDA. Teva expects mid-single digit price erosion in the base US business,are 11 stocks that brokerage firms are watching out today. Indian pharma companies Nomura has a buy ratings on Dr Reddy’s , Glenmark , Alkem , Cadila and Jubilant Life
. It says Teva’s 2017 guidanceis lower than what was presented in 2016-2020 prelim outlook and implies a shortfall of USD 1.5-2 billion in EBITDA.Teva expects mid-single digit price erosion in the base US business. JP Morgan is overweight on Aurobindo Pharma with target at Rs 900 per share on valuation discount to large cap peers narrowed to over 30 percent. It says the stock may see re-rating from monetisation of strong pipeline for the US. Info Edge Bank of America Merrill Lynch has downgraded it to neutral from buy on risks to earnings of recruitment, realty & Zomato business. It has also cut target by 7 percent to Rs 924 per share as headwinds in recruitment, 99acres & Zomato persist. It says Zomato’s valuation declines to USD 600-900 million, then Info Edge’s valuation will decline by 3-11 percent. Lupin Credit Suisse maintains underperform rating with target unchanged at Rs 1350 per share as it is likely to see less competition in Glumetza in the next two quarters.
Sadbhav Engineering Credit Suisse maintains outperform rating with target unchanged at Rs 375 per share as data suggests significant demonetisation impact on traffic. It says several projects have seen double-digit (13-17 percent) decline in December in collection. It is positive on stock based on broad opportunity basket, expected improvement in traffic lower interest rates and healthy balancesheet. Bharti Airtel Bank of America Merrill Lynch cuts FY 17-19 earnings per share (eps) by 4-6 percent and target by 4 percent to Rs 361 per share. It says if Telenor acquisition talks is revenue market share would increase from 33.4 percent to 35.3 percent and spectrum market share would increase from 21.5 percent to 22.8 percent. JSW Energy CLSA recommends selling into any strength in the stock but cuts target to Rs 63 from Rs 65 per share. Key headwinds are merchant power demand, 65 percent coal price rise in 2016. FY 16 performance was peak profitability while high merchant tariffs in south India are likely to correct over the next 12 months.
Read more for HNI Stock Tips-http://www.aceinvestmentadvisory.com
11 stocks that analysts are watching out today Nomura has a buy ratings on Dr Reddy’s, Glenmark, Alkem, Cadila and Jubilant Life. It says Teva’s 2017 guidanceis lower than what was presented in 2016-2020 prelim outlook and implies a shortfall of USD 1.5-2 billion in EBITDA. Teva expects mid-single digit price erosion in the base US business,are 11 stocks that brokerage firms are watching out today. Indian pharma companies Nomura has a buy ratings on Dr Reddy’s , Glenmark , Alkem , Cadila and Jubilant Life
. It says Teva’s 2017 guidanceis lower than what was presented in 2016-2020 prelim outlook and implies a shortfall of USD 1.5-2 billion in EBITDA.Teva expects mid-single digit price erosion in the base US business. JP Morgan is overweight on Aurobindo Pharma with target at Rs 900 per share on valuation discount to large cap peers narrowed to over 30 percent. It says the stock may see re-rating from monetisation of strong pipeline for the US. Info Edge Bank of America Merrill Lynch has downgraded it to neutral from buy on risks to earnings of recruitment, realty & Zomato business. It has also cut target by 7 percent to Rs 924 per share as headwinds in recruitment, 99acres & Zomato persist. It says Zomato’s valuation declines to USD 600-900 million, then Info Edge’s valuation will decline by 3-11 percent. Lupin Credit Suisse maintains underperform rating with target unchanged at Rs 1350 per share as it is likely to see less competition in Glumetza in the next two quarters.
Sadbhav Engineering Credit Suisse maintains outperform rating with target unchanged at Rs 375 per share as data suggests significant demonetisation impact on traffic. It says several projects have seen double-digit (13-17 percent) decline in December in collection. It is positive on stock based on broad opportunity basket, expected improvement in traffic lower interest rates and healthy balancesheet. Bharti Airtel Bank of America Merrill Lynch cuts FY 17-19 earnings per share (eps) by 4-6 percent and target by 4 percent to Rs 361 per share. It says if Telenor acquisition talks is revenue market share would increase from 33.4 percent to 35.3 percent and spectrum market share would increase from 21.5 percent to 22.8 percent. JSW Energy CLSA recommends selling into any strength in the stock but cuts target to Rs 63 from Rs 65 per share. Key headwinds are merchant power demand, 65 percent coal price rise in 2016. FY 16 performance was peak profitability while high merchant tariffs in south India are likely to correct over the next 12 months.
Read more for HNI Stock Tips-http://www.aceinvestmentadvisory.com
